CRISPR$10.9 million. That is how much Editas Medicine has spent so far this year on legal fees incurred by the Broad Institute and Harvard. Most of that money has been spent to defend CRISPR invention patents held by Editas co-founder and Broad scientist Feng Zhang.

This figure was disclosed as part of the company’s latest 10-Q filing with the Securities and Exchange Commission, and according to STAT News has raised a few eyebrows in the sector.  

Sharon Begley writes: “Law professor Jacob Sherkow of New York Law School, an expert in intellectual property law who has been following the CRISPR fight closely, called the legal bill “a lot even by patent litigation standards” He had expected the dispute, “from soup to nuts,” to come in at less than $10 million a side. (The University of California, Berkeley has challenged CRISPR patents issued to the Broad and Harvard University.)”

Read the rest of the STAT News article here.

More on these topics